Xuebijing (XBJ)
Jump to navigation
Jump to search
Introduction
herbal-based intravenous preparation
Indications
- licensed in 2004 by the National Medical Products Administration (NMPA, China) for treatment of sepsis & multiple organ dysfunction syndrome (septic shock)
- reduces mortality in patients with sepsis
- can prevent the development of organ dysfunction in acute insults.
Mechanism of action
- Chinese medicine containing extracts from:[2]
- Carthamus tinctorius L. (Carthami Flos, hong hua, Asteraceae)
- Paeonia lactiflora Pall. (Paeoniae radix rubra, chi shao, Ranunculaceae)
- Ligusticum chuanxiong Hort. (Chuanxiong Rhizoma, chuan xiong, Umbelliferae)
- Salvia miltiorrhiza Bge. (Salviae miltiorrhizae Radix Et Rhizoma, dan shen, Labiatae)
- Angelica sinensis (Oliv.) Diels (Angelicae sinensis Radix, dang gui, Umbelliferae)
- antagonistic effect on endotoxin
- inhibitory effect on uncontrolled release of endogenous inflammatory mediators produced by endotoxin-stimulated monocytes/macrophages
- can improve coagulation disorders present in disseminated intravascular coagulation
- can increase activity of superoxide dismutase
- can regulate hypersensitive or hyposensitive immune responses
More general terms
- pharmaceutical herb; medicinal herb; herbal supplement; botanical
- traditional Chinese medicine (TCM)
- pharmacologic combination
References
- ↑ Liu S, Yao C, Xie J et al Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis. The EXIT-SEP Randomized Clinical Trial. JAMA Intern Med. Published online May 1, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37126332 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2804120
Unger EF, Clissold DB Xuebijing Injection for the Treatment of Sepsis. What Would a Path to FDA Approval Look Like? JAMA Intern Med. Published online May 1, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37126325 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2804125 - ↑ 2.0 2.1 Li C, Wang P, Li M, Zheng R et al The current evidence for the treatment of sepsis with Xuebijing injection: Bioactive constituents, findings of clinical studies and potential mechanisms. J Ethnopharmacol. 2021 Jan 30;265:113301. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32860891 Review